QLGN: Gunggung utang perusahaan Qualigen Therapeutics, Inc.

Market fluctuations in Qualigen Therapeutics (QLGN) share prices reflect the dynamics of a specific debt, which currently stands at 0.00. The business relies on the FastPack system, which accelerates oncology and virus diagnostics for physicians. Qualigen Therapeutics (QLGN) is also developing nanotechnological cancer treatments aimed at long-term patent ownership. Currently, the strategy has shifted from acquisitions toward seeking profit through partnerships with small laboratories.

The scale of operations at Qualigen Therapeutics (QLGN) requires strict liability control, meaning the current debt of 0.00 reflects the aggregate volume of external loans and credits. This metric measures financial leverage and default risk, which is critical for a company restoring the medical community's confidence in its technologies by ensuring debt sustainability and balance sheet transparency.